Pub Date : 2026-03-01Epub Date: 2026-02-10DOI: 10.1016/j.clinthera.2026.01.001
Sang Hyun Lee MD, PhD , Kyungil Park MD, PhD , Ki Hong Lee MD, PhD , Yoonhaeng Cho MD, PhD , Dae-Hee Kim MD, PhD , Sungmin Lim MD, PhD , Seong Bo Yoon MD, PhD , Jae-Sik Jang MD, PhD , Hong-Seok Lim MD, PhD , Joon-Hyung Doh MD, PhD , Dae-Young Kim MD , Il Suk Sohn MD, PhD , Dae Young Cheon MD , Myung Hwan Bae MD, PhD , Sung Hea Kim MD, PhD , Yonggu Lee MD, PhD , Sang Hyun Ihm MD, PhD , Rak Kyeong Choi MD, PhD , Hun-Jun Park MD, PhD , Wook Bum Pyun MD, PhD , Jinho Shin MD, PhD
Purpose
This randomized, double-blind, multicenter, phase III clinical trial aimed to evaluate the efficacy and safety of telmisartan 20 mg and s-amlodipine 1.25 mg, a fixed-dose combination (Tel/S-Amlo) versus telmisartan 20 mg single therapy or s-amlodipine 1.25 mg single therapy for initial treatment in patients with hypertension.
Methods
After a wash-out/therapeutic lifestyle change period of ≥4 weeks, a total of 235 eligible patients were randomized and received 1 of 3 treatments for 8 weeks: (1) telmisartan 20 mg/s-amlodipine 1.25 mg (Tel/S-Amlo), (2) telmisartan 20 mg (Tel), or (3) S-amlodipine 1.25 mg (S-Amlo). The primary endpoint was the efficacy evaluation of Tel/S-Amlo by comparing changes in mean sitting systolic blood pressure (msSBP) from baseline after 8 weeks of treatment.
Findings
At 8 weeks, the least square (LS) mean (SE) change in msSBP was −20.04 (1.46) mm Hg in the Tel/S-Amlo group, compared with –16.44 (1.46) mm Hg in the Tel group (between-group difference –3.60 (1.78) mm Hg, P-value = 0.0451). Similarly, the Tel/S-Amlo group showed a change of −21.12 (1.33) mm Hg versus −15.58 (1.32) mm Hg in the S-Amlo group (between-group difference –5.53 (1.61) mm Hg, P-value = 0.0008). There were no statistically significant differences in the incidence of overall AEs and adverse drug reactions among the 3 groups, and no serious adverse events occurred during the study.
Implications
Combination therapy with a low-dose of telmisartan and s-amlodipine may be a promising initial treatment for patients with hypertension.
Clinical trial registration
This study was registered in ClinicalTrials.gov (NCT06121518).
{"title":"Efficacy and Safety of Combination Therapy With Low Dose of Telmisartan and S-Amlodipine in Patients With Hypertension: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase III Clinical Trial","authors":"Sang Hyun Lee MD, PhD , Kyungil Park MD, PhD , Ki Hong Lee MD, PhD , Yoonhaeng Cho MD, PhD , Dae-Hee Kim MD, PhD , Sungmin Lim MD, PhD , Seong Bo Yoon MD, PhD , Jae-Sik Jang MD, PhD , Hong-Seok Lim MD, PhD , Joon-Hyung Doh MD, PhD , Dae-Young Kim MD , Il Suk Sohn MD, PhD , Dae Young Cheon MD , Myung Hwan Bae MD, PhD , Sung Hea Kim MD, PhD , Yonggu Lee MD, PhD , Sang Hyun Ihm MD, PhD , Rak Kyeong Choi MD, PhD , Hun-Jun Park MD, PhD , Wook Bum Pyun MD, PhD , Jinho Shin MD, PhD","doi":"10.1016/j.clinthera.2026.01.001","DOIUrl":"10.1016/j.clinthera.2026.01.001","url":null,"abstract":"<div><h3>Purpose</h3><div>This randomized, double-blind, multicenter, phase III clinical trial aimed to evaluate the efficacy and safety of telmisartan 20 mg and s-amlodipine 1.25 mg, a fixed-dose combination (Tel/S-Amlo) versus telmisartan 20 mg single therapy or s-amlodipine 1.25 mg single therapy for initial treatment in patients with hypertension.</div></div><div><h3>Methods</h3><div>After a wash-out/therapeutic lifestyle change period of ≥4 weeks, a total of 235 eligible patients were randomized and received 1 of 3 treatments for 8 weeks: (1) telmisartan 20 mg/s-amlodipine 1.25 mg (Tel/S-Amlo), (2) telmisartan 20 mg (Tel), or (3) S-amlodipine 1.25 mg (S-Amlo). The primary endpoint was the efficacy evaluation of Tel/S-Amlo by comparing changes in mean sitting systolic blood pressure (msSBP) from baseline after 8 weeks of treatment.</div></div><div><h3>Findings</h3><div>At 8 weeks, the least square (LS) mean (SE) change in msSBP was −20.04 (1.46) mm Hg in the Tel/S-Amlo group, compared with –16.44 (1.46) mm Hg in the Tel group (between-group difference –3.60 (1.78) mm Hg, <em>P</em>-value = 0.0451). Similarly, the Tel/S-Amlo group showed a change of −21.12 (1.33) mm Hg versus −15.58 (1.32) mm Hg in the S-Amlo group (between-group difference –5.53 (1.61) mm Hg, <em>P</em>-value = 0.0008). There were no statistically significant differences in the incidence of overall AEs and adverse drug reactions among the 3 groups, and no serious adverse events occurred during the study.</div></div><div><h3>Implications</h3><div>Combination therapy with a low-dose of telmisartan and s-amlodipine may be a promising initial treatment for patients with hypertension.</div></div><div><h3>Clinical trial registration</h3><div>This study was registered in ClinicalTrials.gov (NCT06121518).</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"48 3","pages":"Pages 240-246"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146164543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-17DOI: 10.1016/j.clinthera.2026.01.011
Jill L. Maron MD, MPH
{"title":"The Use of Ensemble Large Language Models to Predict Patient Nonadherence","authors":"Jill L. Maron MD, MPH","doi":"10.1016/j.clinthera.2026.01.011","DOIUrl":"10.1016/j.clinthera.2026.01.011","url":null,"abstract":"","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"48 3","pages":"Page 213"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146218971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-02-26DOI: 10.1016/j.clinthera.2026.01.012
Stephanie Pisciella MD , Nicholas G. Guerina MD, PhD
{"title":"A Century of Antibiotic War on Neisseria gonorrhoeae: New Hope With New First-in-Class Drug Developments","authors":"Stephanie Pisciella MD , Nicholas G. Guerina MD, PhD","doi":"10.1016/j.clinthera.2026.01.012","DOIUrl":"10.1016/j.clinthera.2026.01.012","url":null,"abstract":"","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"48 3","pages":"Pages 296-298"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147316735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-01-27DOI: 10.1016/j.clinthera.2025.12.017
Zhilan Zhou , Lurong Yu , Jiaoni Zheng , Yao He , Lili Xia , Qingyan Jia , Limei Liu
Purpose
Avacopan emerges as a significant therapeutic agent for the condition known as antineutrophil cytoplasmic antibody–associated vasculitis. However, there is a lack of current real-world safety studies with large sample sizes. The objective of this study is to scrutinize avacopan’s postcommercialization safety profile, thereby providing an informed foundation for its clinical application.
Methods
Using 2 methods, including the Bayesian confidence propagation neural network and reporting odds ratio (ROR), we conducted signal mining on all avacopan adverse event reports in the US Food and Drug Administration Adverse Event Reporting System from the third quarter of 2021 to the fourth quarter of 2024 to evaluate the safety profile of avacopan.
Findings
The US Food and Drug Administration Adverse Event Reporting System database recorded 7141 adverse events related to avacopan, involving 3135 patients. The proportion of female patients who experienced adverse events is higher than that of male patients. We found that 225 patients died, with more deaths among those aged 65 years and above and male patients. This signal mining identified 17 systemic organ classifications, including a total of 136 adverse eventsignals, such as antineutrophil cytoplasmic antibody increased (ROR = 357.69; 95% CI, 150.92–847.75; information coefficient = 8.27; lower limit of the CI = 1.60), biopsy kidney (ROR = 106.68; 95% CI, 33.48–339.94; information coefficient = 6.67; lower limit of the CI = 0.47). In addition, we also discovered new adverse events, such as alopecia, sepsis, pulmonary hemorrhage, hypertransaminasemia, deafness, and insomnia.
Implications
This study reveals the potential risks of avacopan use and found significant differences in adverse events between genders and age groups. Further prospective studies are needed to validate the current findings, refine risk warnings and monitoring strategies for different populations, and explore strategies to reduce or prevent adverse reactions.
{"title":"Profiling of Potential Postmarket Risk Tracking and Pharmacovigilance Data for Avacopan","authors":"Zhilan Zhou , Lurong Yu , Jiaoni Zheng , Yao He , Lili Xia , Qingyan Jia , Limei Liu","doi":"10.1016/j.clinthera.2025.12.017","DOIUrl":"10.1016/j.clinthera.2025.12.017","url":null,"abstract":"<div><h3>Purpose</h3><div>Avacopan emerges as a significant therapeutic agent for the condition known as antineutrophil cytoplasmic antibody–associated vasculitis. However, there is a lack of current real-world safety studies with large sample sizes. The objective of this study is to scrutinize avacopan’s postcommercialization safety profile, thereby providing an informed foundation for its clinical application.</div></div><div><h3>Methods</h3><div>Using 2 methods, including the Bayesian confidence propagation neural network and reporting odds ratio (ROR), we conducted signal mining on all avacopan adverse event reports in the US Food and Drug Administration Adverse Event Reporting System from the third quarter of 2021 to the fourth quarter of 2024 to evaluate the safety profile of avacopan.</div></div><div><h3>Findings</h3><div>The US Food and Drug Administration Adverse Event Reporting System database recorded 7141 adverse events related to avacopan, involving 3135 patients. The proportion of female patients who experienced adverse events is higher than that of male patients. We found that 225 patients died, with more deaths among those aged 65 years and above and male patients. This signal mining identified 17 systemic organ classifications, including a total of 136 adverse eventsignals, such as antineutrophil cytoplasmic antibody increased (ROR = 357.69; 95% CI, 150.92–847.75; information coefficient = 8.27; lower limit of the CI = 1.60), biopsy kidney (ROR = 106.68; 95% CI, 33.48–339.94; information coefficient = 6.67; lower limit of the CI = 0.47). In addition, we also discovered new adverse events, such as alopecia, sepsis, pulmonary hemorrhage, hypertransaminasemia, deafness, and insomnia.</div></div><div><h3>Implications</h3><div>This study reveals the potential risks of avacopan use and found significant differences in adverse events between genders and age groups. Further prospective studies are needed to validate the current findings, refine risk warnings and monitoring strategies for different populations, and explore strategies to reduce or prevent adverse reactions.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"48 3","pages":"Pages 247-257"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147453831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-08-26DOI: 10.1016/j.clinthera.2025.08.002
Hongda Xu , Tuocen Fan , Yiyang Xu , Wenhao Li , Junrui Cui
{"title":"Comment on: The Effect of Intermittent Fasting Diet in Comparison With Low-Calorie Diet on Inflammation, Lipid Profile, Glycemic Index, Liver Fibrosis in Patients With Metabolic-Associated Fatty Liver Disease (MAFLD): A Randomized Controlled Trial","authors":"Hongda Xu , Tuocen Fan , Yiyang Xu , Wenhao Li , Junrui Cui","doi":"10.1016/j.clinthera.2025.08.002","DOIUrl":"10.1016/j.clinthera.2025.08.002","url":null,"abstract":"","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"48 3","pages":"Pages 289-290"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cardiovascular diseases (CVD) affect about 6% of the global population and are a leading cause of death. Gout impacts approximately 3% of the population, and many do not receive adequate urate-lowering therapy to prevent disease progression. Gout is frequent in patients with CVD, and poorly managed gout is associated with cardiovascular complications, warranting proper gout treatment. This study assessed adherence to recommended gout treatment in patients with CVD.
Methods
From a prospective cohort of gout patients confirmed by microscopy-identified urate crystals, we identified those with concomitant CVD (ischemic heart disease, atrial fibrillation, or heart failure). Patients were treated in real-life healthcare settings. The primary outcome was achieving recommended target serum urate levels 2 years postdiagnosis: <0.36 mmol/L for general gout management and <0.30 mmol/L for patients with tophi.
Results
Of 286 gout patients, 117 (41%) had CVD. The median age was 71 years, 76% were male, and most had multiple comorbidities. Recommended urate levels to prevent disease progression were achieved by 59%. However, 45% had tophi at diagnosis, and only 33% of these achieved levels sufficient to dissolve tophi. The mean prescribed dose of allopurinol was 253 mg/day, which was often insufficient to achieve target urate levels.
Conclusion
Gout in patients with CVD is often inadequately managed, potentially increasing the risk of serious cardiovascular events. These findings reflect typical treatment settings. Optimizing allopurinol dosing and adherence to gout treatment guidelines may improve gout-related outcomes and could potentially have implications for cardiovascular risk. These findings highlight gout as a relevant comorbidity in patients with CVD and suggest that greater attention to gout management in cardiovascular care pathways may be warranted.
{"title":"Unseen but Impactful: Gout as a Neglected Comorbidity in Cardiovascular Care","authors":"Zaayneb Sediqi MD , Oliver Buchhave Pedersen MD, PhD , Søren Jepsen PhD , Steen Hylgaard Jørgensen MD, PhD , Claus Rasmussen MD, PhD","doi":"10.1016/j.clinthera.2026.01.006","DOIUrl":"10.1016/j.clinthera.2026.01.006","url":null,"abstract":"<div><h3>Background</h3><div>Cardiovascular diseases (CVD) affect about 6% of the global population and are a leading cause of death. Gout impacts approximately 3% of the population, and many do not receive adequate urate-lowering therapy to prevent disease progression. Gout is frequent in patients with CVD, and poorly managed gout is associated with cardiovascular complications, warranting proper gout treatment. This study assessed adherence to recommended gout treatment in patients with CVD.</div></div><div><h3>Methods</h3><div>From a prospective cohort of gout patients confirmed by microscopy-identified urate crystals, we identified those with concomitant CVD (ischemic heart disease, atrial fibrillation, or heart failure). Patients were treated in real-life healthcare settings. The primary outcome was achieving recommended target serum urate levels 2 years postdiagnosis: <0.36 mmol/L for general gout management and <0.30 mmol/L for patients with tophi.</div></div><div><h3>Results</h3><div>Of 286 gout patients, 117 (41%) had CVD. The median age was 71 years, 76% were male, and most had multiple comorbidities. Recommended urate levels to prevent disease progression were achieved by 59%. However, 45% had tophi at diagnosis, and only 33% of these achieved levels sufficient to dissolve tophi. The mean prescribed dose of allopurinol was 253 mg/day, which was often insufficient to achieve target urate levels.</div></div><div><h3>Conclusion</h3><div>Gout in patients with CVD is often inadequately managed, potentially increasing the risk of serious cardiovascular events. These findings reflect typical treatment settings. Optimizing allopurinol dosing and adherence to gout treatment guidelines may improve gout-related outcomes and could potentially have implications for cardiovascular risk. These findings highlight gout as a relevant comorbidity in patients with CVD and suggest that greater attention to gout management in cardiovascular care pathways may be warranted.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"48 3","pages":"Pages 226-231"},"PeriodicalIF":3.6,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146257688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-24DOI: 10.1016/j.clinthera.2026.01.013
Lu-Hsuan Wu, Ching-Lan Cheng, Yea-Huei Kao Yang, Swu-Jane Lin
{"title":"Corrigendum to \"A Nationwide Cohort Study on Antidepressant Use and Stroke Risk in Young Adults Aged 18-44 Years\" [Clin Ther. 2025;47:720-728].","authors":"Lu-Hsuan Wu, Ching-Lan Cheng, Yea-Huei Kao Yang, Swu-Jane Lin","doi":"10.1016/j.clinthera.2026.01.013","DOIUrl":"https://doi.org/10.1016/j.clinthera.2026.01.013","url":null,"abstract":"","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147303191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-23DOI: 10.1016/j.clinthera.2026.01.014
Wei Wang, Jun Guo, Bo Chen, Zhijian Lan, Yongjin Fang
Purpose: To assess the effect of etomidate injection on succinylcholine-induced fasciculations through a randomized controlled trial.
Methods: Intravenous succinylcholine (2 mg/kg) was administered to 100 adult patients undergoing elective vocal cord surgery, with allocation to two groups: immediate group, where succinylcholine was administered immediately, and delayed group, where succinylcholine was administered 15 sec after injection of etomidate 0.2 mg/kg. The two groups were compared in terms of the severity and duration of muscle fasciculation caused by succinylcholine and the incidence of postoperative myalgia.
Findings: The severity of fasciculations graded on a 4-point scale was considered the primary outcome. Compared with the delayed group, the immediate group exhibited substantially reduced fasciculation severity scores (P = 0.005). A lower incidence of postoperative myalgia was observed in the immediate group than in the delayed group (P = 0.031). Furthermore, in the delayed group, the heart rate after intervention decreased more significantly (P = 0.014). No differences in other adverse effects were observed.
Implications: The severity of succinylcholine-induced fasciculations and the incidence of postoperative myalgia were significantly reduced without adversely affecting intubation conditions or hemodynamics by injecting a 0.2 mg/kg dose of etomidate immediately before administering 2 mg/kg succinylcholine.
{"title":"Effects of Etomidate Injection on Succinylcholine-Induced Fasciculation.","authors":"Wei Wang, Jun Guo, Bo Chen, Zhijian Lan, Yongjin Fang","doi":"10.1016/j.clinthera.2026.01.014","DOIUrl":"https://doi.org/10.1016/j.clinthera.2026.01.014","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the effect of etomidate injection on succinylcholine-induced fasciculations through a randomized controlled trial.</p><p><strong>Methods: </strong>Intravenous succinylcholine (2 mg/kg) was administered to 100 adult patients undergoing elective vocal cord surgery, with allocation to two groups: immediate group, where succinylcholine was administered immediately, and delayed group, where succinylcholine was administered 15 sec after injection of etomidate 0.2 mg/kg. The two groups were compared in terms of the severity and duration of muscle fasciculation caused by succinylcholine and the incidence of postoperative myalgia.</p><p><strong>Findings: </strong>The severity of fasciculations graded on a 4-point scale was considered the primary outcome. Compared with the delayed group, the immediate group exhibited substantially reduced fasciculation severity scores (P = 0.005). A lower incidence of postoperative myalgia was observed in the immediate group than in the delayed group (P = 0.031). Furthermore, in the delayed group, the heart rate after intervention decreased more significantly (P = 0.014). No differences in other adverse effects were observed.</p><p><strong>Implications: </strong>The severity of succinylcholine-induced fasciculations and the incidence of postoperative myalgia were significantly reduced without adversely affecting intubation conditions or hemodynamics by injecting a 0.2 mg/kg dose of etomidate immediately before administering 2 mg/kg succinylcholine.</p>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147282691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-14DOI: 10.1016/j.clinthera.2026.01.008
Yi Cai
{"title":"Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy-Insights and Perspectives.","authors":"Yi Cai","doi":"10.1016/j.clinthera.2026.01.008","DOIUrl":"https://doi.org/10.1016/j.clinthera.2026.01.008","url":null,"abstract":"","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146200472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号